ロード中...
Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer
Treatment for ovarian cancer remains challenging despite a high initial response rate to first line platinum-taxane treatment. Most patients eventually experience recurrence and require further treatment. Persistent activation of STAT3 is associated with cancer growth and progression and is also inv...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5966246/ https://ncbi.nlm.nih.gov/pubmed/29849942 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24368 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|